These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 16185173)

  • 1. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.
    Mohr JF; McKinnon PS; Peymann PJ; Kenton I; Septimus E; Okhuysen PC
    Pharmacotherapy; 2005 Oct; 25(10):1303-9. PubMed ID: 16185173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients.
    Lodise T; Graves J; Miller C; Mohr JF; Lomaestro B; Smith RP
    Pharmacotherapy; 2007 Nov; 27(11):1498-505. PubMed ID: 17963459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting.
    LaPlante KL; Mersfelder TL; Ward KE; Quilliam BJ
    Pharmacotherapy; 2008 Jan; 28(1):82-9. PubMed ID: 18154478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study.
    Graumlich JF; Habis S; Avelino RR; Salverson SM; Gaddamanugu M; Jamma K; Aldag JC
    Pharmacotherapy; 2005 Oct; 25(10):1296-302. PubMed ID: 16185172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis.
    Mohr JF; Peymann PJ; Troxell E; Lodise TP; Ostrosky-Zeichner L
    Clin Ther; 2008 Jan; 30(1):152-7. PubMed ID: 18343251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe dysglycemia with the fluoroquinolones: a class effect?
    Aspinall SL; Good CB; Jiang R; McCarren M; Dong D; Cunningham FE
    Clin Infect Dis; 2009 Aug; 49(3):402-8. PubMed ID: 19545207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient gatifloxacin therapy and dysglycemia in older adults.
    Park-Wyllie LY; Juurlink DN; Kopp A; Shah BR; Stukel TA; Stumpo C; Dresser L; Low DE; Mamdani MM
    N Engl J Med; 2006 Mar; 354(13):1352-61. PubMed ID: 16510739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
    Chou HW; Wang JL; Chang CH; Lee JJ; Shau WY; Lai MS
    Clin Infect Dis; 2013 Oct; 57(7):971-80. PubMed ID: 23948133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose homeostasis abnormalities associated with use of gatifloxacin.
    Frothingham R
    Clin Infect Dis; 2005 Nov; 41(9):1269-76. PubMed ID: 16206101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of the effects of gatifloxacin on glucose homeostasis.
    Onyenwenyi AJ; Winterstein AG; Hatton RC
    Pharm World Sci; 2008 Oct; 30(5):544-9. PubMed ID: 18297409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin.
    Mathews S; Cole J; Ryono RA
    Pharmacotherapy; 2006 Oct; 26(10):1446-52. PubMed ID: 16999655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
    Frothingham R
    Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gatifloxacin induced abnormalities in glucose homeostasis in a patient on glimepiride.
    Kesavadev J; Rasheed SA
    J Assoc Physicians India; 2006 Dec; 54():951-2. PubMed ID: 17334014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolone-associated dysglycemias: a tale of two toxicities.
    Owens RC
    Pharmacotherapy; 2005 Oct; 25(10):1291-5. PubMed ID: 16185171
    [No Abstract]   [Full Text] [Related]  

  • 15. Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature.
    Yip C; Lee AJ
    Clin Ther; 2006 Nov; 28(11):1857-66. PubMed ID: 17213006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy.
    LeBlanc M; Bélanger C; Cossette P
    Pharmacotherapy; 2004 Jul; 24(7):926-31. PubMed ID: 15303456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gatifloxacin-induced histamine release and hyperglycemia in rats.
    Ishiwata Y; Yasuhara M
    Eur J Pharmacol; 2010 Oct; 645(1-3):192-7. PubMed ID: 20674567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gatifloxacin-induced dysglycemia.
    Zvonar R
    Am J Health Syst Pharm; 2006 Nov; 63(21):2087-92. PubMed ID: 17057046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.